Document:

<PAGE>
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                                                                   EXHIBIT 10.16

                          THE JOHNS HOPKINS UNIVERSITY

                        BIONUMERIK PHARMACEUTICALS, INC.

          JOINT COLLABORATION, LICENSING, AND CLINICAL TRIALS AGREEMENT

      THIS AGREEMENT (the "Agreement") is made as of February 9, 2005 (the
"Effective Date") by and between The Johns Hopkins University, organized and
existing under the laws of the State of Maryland with a principal place of
business at 733 North Broadway Avenue, Baltimore, Maryland 21205 (the
"University") and BioNumerik Pharmaceuticals, Inc., a Texas corporation with its
principal place of business at Suite 1250, 8122 Datapoint Drive, San Antonio,
Texas 78229 (the "Company").

                                    RECITALS

      WHEREAS the Company wishes to obtain the opportunity to discuss new
technical developments with a view to potential licenses of certain inventions
discovered and/or developed at the Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins (the "Center");

      WHEREAS the Center believes that the Company is skillful in the
commercialization of pharmaceutical compounds and seeks to benefit economically
from the Company's efforts;

      WHEREAS the Center desires to conduct certain clinical trials for the
Company on an agreed basis;

      WHEREAS in consideration of such basis, the Company is willing to give the
Center certain first option rights on any clinical trials to be conducted by the
Company; and

      WHEREAS in consideration for these collaborations, the Company will pay to
the Center [**] with the execution and delivery of this Agreement and an
additional [**] on each of the next [**] anniversaries thereof.

      NOW, THEREFORE, the Parties agree as follows:

                                     PART I

                             TECHNICAL COLLABORATION

      1.1 General. This Agreement anticipates a five-year collaboration between
the University and the Company (the "Collaboration") providing for the further
development by the Company of compounds invented by members of the faculty of
the Center (collectively, the "Center Faculty") for the treatment of solid
tumors and hematologic malignancies and the potential applications of such
compounds ("Oncology Drugs").

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>

      1.2 Term. The Collaboration will take place during the period commencing
on the Effective Date and continuing for five years thereafter, provided that
the Collaboration and this Agreement may be earlier terminated by either the
University or the Company by providing written notice to the other party at
least 90 days prior to the anniversary date of the Effective Date (the "Next
Anniversary Date") that next follows the date on which such notice of
termination is provided.

            In the event of such a notice of termination, this Agreement and all
rights and obligations of the University and the Company hereunder shall
terminate effective as of the Next Anniversary Date, provided that the rights
and obligations under Sections 1.3, 1.4, 1.6, 1.9, 1.10, and 1.11 of this
Agreement shall survive any such termination and continue in effect in
accordance with their terms. In addition, in the event of such an early
termination pursuant to this Section 1.2, the Company shall have no further
obligation to make payments that would otherwise be due under Part III, Section
3.1 of this Agreement with respect to anniversaries of the Effective Date of
this Agreement that occur after the date such notice of termination is provided
in accordance with this Section 1.2.

      1.3 Company's Option.

      (a) The University hereby grants to the Company a first option to a
worldwide, royalty bearing, exclusive license to inventions of the Center
Faculty that are made in the course of performing research funded by this
Agreement, subject to the rights of any additional sponsors including U.S.
Government rights under 35 U.S.C. Sections 200-212. Inventions discovered
through research funded by the Company are hereinafter referred to as
"University Inventions". Within 90 days after any termination of this Agreement,
the University will provide the Company with an Invention Notice of any
University Inventions with respect to which the Company has not been previously
notified.

      (b) The University hereby grants to the Company a first option to a
worldwide, royalty bearing, exclusive license to selected Oncology Drugs
invented by Center Faculty without the Company's financial support and which are
unencumbered by the licensing rights of commercial third parties. Inventions
discovered without the Company's financial support are hereinafter referred to
as "Selected Inventions."

      (c) The Company shall have sixty (60) days from the date of receipt of an
Invention Notice (defined in Section 1.6) to request that the parties enter
license negotiations. In the event that the Company and the University determine
to enter into a license negotiation with respect to a University Invention or
Selected Invention, the University and the Company will begin such negotiations
using the general license form attached hereto as Exhibit A but further
negotiation between the parties will be unrestricted. The Office of Technology
Licensing of the University's School of Medicine will represent the University
in such negotiations.

                                      -2-
<PAGE>

      1.4 Ownership of Collaboration Results. All inventions and discoveries
shall be owned by the party making the invention or discovery. Any inventions
deemed to be jointly made by the Company and the University shall be owned
jointly by the Company and the University and subject to their respective
license. Record title to patents and patent applications for University
Inventions and/or Selected Inventions shall be held by the University. Record
title to patents and patent applications for inventions made jointly by the
University and the Company shall be joint and subject to their respective
license.

      1.5 Other Collaborations. Each of the University and the Company shall be
free to conduct other research, whether under the sponsorship of or in
collaboration with, the federal government or other third parties, or otherwise,
provided that the terms and conditions of any such research, sponsorships, or
collaborations shall not conflict with the terms of this Agreement.

      1.6 Notice. The Center Faculty will promptly notify the Office of
Technology Licensing of the University's School of Medicine (the "Licensing
Office") in writing of any University Invention or Selected Invention (the
"Invention Notice"). The Invention Notice will include a detailed written
description of such invention. When a University Invention is not encumbered by
the licensing rights of commercial third parties, the Licensing Office shall
notify the director of the Center, who will promptly submit the Invention Notice
to the Company. In the case of a Selected Invention, the Licensing Office and
the director of the Center will review the Selected Invention and jointly
determine whether the Company is a logical licensee, who is as capable of
developing and commercializing the Selected Invention as other potential
licensees. If the Licensing Office and the director of the Center agree that the
Company is the logical licensee, the director of the Center will promptly submit
the Invention Notice to the Company.

      1.7 Educational Advancement. The University does not guarantee that any
patentable or non-patentable Oncology Drugs will result from the Collaboration.
The Company understands that the University's primary mission is educational and
that the Collaboration is intended to forward that mission.

      1.8 Consultation. The Company will make available its chief-executive
officer, Frederick H. Hausheer, M.D. ("Dr. Hausheer"), to confer on-site, one
day per year, with the Center, the Center Faculty, and the Center's
investigators and researchers concerning Oncology Drugs developed by the Center
Faculty. Dr. Hausheer's consultations will be without charge to the University.

      1.9 Confidentiality. During the period this Agreement is in effect and for
a period of three (3) years thereafter, the University and the Company agree to
keep in confidence and to use solely as contemplated in this Agreement all
information received from the other party under this Agreement or obtained
pursuant to or in connection with the Collaboration. All reasonable efforts will
be used to avoid disclosure to any third party of any information supplied or
developed under this Agreement, unless the prior written consent of the other
party is obtained. The preceding confidentiality requirements will not extend to
any information which (a) is or becomes public knowledge, after the time it
becomes public; (b) the receiving party can show by written or other tangible
evidence was in its possession at the time of disclosure hereunder and

                                      -3-
<PAGE>

which the receiving party without breach of any obligation is free to disclose
to others; (c) was received by the receiving party from a third party who did
not acquire it, directly or indirectly, from the disclosing party under any
obligation of confidentiality and which the third party is free to disclose to
others; (d) is required to be disclosed by a court of law or by the regulations
of a federal agency, subject to the earliest practical notification by the party
obligated to make such disclosure so as to enable the other party to obtain such
protective orders as may be available; or (e) is independently developed by the
receiving party and which the receiving party can show by written or other
tangible evidence was so independently developed.

      1.10 Publication. Notwithstanding the foregoing, and except for
information supplied by the Company and not otherwise known to the University,
the University may publish in scientific journals research results arising from
activities funded by the Company, from University Inventions, and from Selected
Inventions for which the Company is given notice pursuant to Section 1.6, in
accordance with the following procedures:

            (a) the University will submit the proposed manuscript to the
Company at least thirty (30) days prior to submission for publication; and

            (b) within thirty (30) days of the receipt of such manuscript, the
Company will advise the University whether the Company has determined that the
manuscript contains patentable subject matter relating to a University Invention
and whether the Company wishes that a patent application be filed.

      If the Company notifies the University that the manuscript includes no
confidential information and/or that the Company does not wish patent action to
be taken, or if the Company does not so notify the University within the thirty
(30) day period, the University will be free to publish. If the Company wishes
patent action to be taken, it will notify the University of its decision and
patent protection will be sought pursuant to Section 1.11. Neither the
University nor any of its employees will submit the manuscript for publication
or disclose its contents to third parties until patent applications have been
filed. The patent application(s) will be filed within ninety (90) days of the
University's receipt of the Company's notice requesting that the University seek
patent protection. After the earlier of ninety (90) days or the filing of a
patent application, the University will be free to submit and publish the
manuscript. However, no publication of any compounds, structures or other
information which is confidential information of BioNumerik will be made by the
University without the prior written consent of the Company, which consent will
not be unreasonably withheld.

      1.11 Patents. Except as provided in Section 1.10, the Company may for a
period of sixty (60) days after the Company's receipt of the Invention Notice
elect to seek patent protection for any University Invention or Selected
Invention with respect to which it negotiates a license. In the event the
Company determines to seek patent protection, the Company will inform the
University in writing of its election. The University will then cause to be
prepared, filed, prosecuted, and maintained at the Company's expense patent
applications and/or patents resulting therefrom, provided, however, that in the
event that the Company and the University are unable to negotiate a license for
such invention, the Company's liability for any additional patent

                                      -4-
<PAGE>

expenses shall cease upon the University's receipt of the Company's written
notification that it no longer wishes to continue negotiations, and the
University will, upon licensing the invention to a commercial third party,
reimburse the Company for all patent expenses which the Company incurred. Such
patent preparation, filing, prosecution, and maintenance will be performed
through outside patent counsel selected by the University and approved by the
Company, which approval will not be unreasonably withheld. In the event the
Company determines not to seek patent protection as provided herein, the
University will be free to seek such protection at the University's expense.

                                     PART II

                            CLINICAL TRIAL AGREEMENT

      2.1 Clinical Trials. The Company hereby grants to the Center a first
option to negotiate to conduct evaluative clinical trials of Oncology Drugs
developed or invented by the Company (the "Trials"). The first option granted
herein will expire thirty (30) days after the University's receipt of a written
notice identifying the Oncology Drug developed or invented by the Company and
containing an initial draft of the proposed investigational new drug application
("IND") to be filed with the Food and Drug Administration. In the event the
University and the Company are unable to agree upon the material terms of a
clinical trials agreement within such thirty (30) day period, the University's
rights herein shall terminate with respect to that Oncology Drug. In addition,
nothing herein shall prevent the Company from conducting negotiations with other
potential clinical trial sites concurrently with its negotiations with the
University. In connection with any agreement entered with respect to the Trials,
the Company agrees to reimburse the University's direct and indirect costs,
provided, however, that the University agrees that total indirect costs for such
Trials will not exceed [**] of total direct costs, and the costs and terms of
such Trials will otherwise be in accordance with and no less favorable to the
Company than clinical trial agreements Center may have with other sponsors.

                                    PART III

                                PERIODIC PAYMENTS

      3.1 Upon the execution and delivery of this Agreement by the University,
the Company will pay to the Center [**]. Upon each of the next [**] succeeding
anniversaries of the Effective Date of this Agreement, the Company will pay to
the Center an additional [**]. In addition, the Center and the Company will
discuss in good faith and determine a reasonable portion of the above-referenced
annual amount paid to the Center that will be allocated to fund a fellowship or
other research agreed upon by the Company and the Center.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                      -5-
<PAGE>

                                     PART IV

                                  MISCELLANEOUS

      4.1 University Name. The Company will not use the name, likeness, or logo
of the Johns Hopkins University; its Schools, Divisions, Departments, or
Centers; The Johns Hopkins Hospital and Health System; or Johns Hopkins'
faculty, employees, students, or trustees in any of the Company's fund-raising
documents, publications, advertisements, or marketing and promotional materials
without the prior written consent of the University. The University shall have
three business days from the date of receipt of the Company's request for
written consent to review such request.

      4.2 Breach/Default. Upon breach or default of any of the terms and
conditions of this Agreement, the non-defaulting party will deliver a written
notice of such default to the defaulting party (the "Default Notice"). If the
default is not cured within sixty (60) days after the defaulting party's receipt
of the Default Notice, the non-defaulting party may terminate this Agreement
upon written notice provided by the non-defaulting party to the defaulting
party.

      4.3 Assignment. This Agreement may not be assigned or transferred by any
party without the prior written consent of the parties, provided, however, that
the Company may assign or transfer its rights and obligations under this
Agreement to a successor to all or substantially all of its assets or business,
whether by sale, merger, operation of law, or otherwise, and the Company shall
provide written notice to the University of any such assignment.

      4.4 Independent Contractor. For the purposes of this Agreement and all
services to be provided hereunder, the parties will be and will be deemed to be
independent contractors and not agents or employees of the other party. Neither
party will have authority to make any statement, representation, or commitment
of any kind, or to take any action which will be binding on the other party,
except as may be expressly provided for herein or authorized in writing.

      4.5 Waiver and Amendment. The terms of this Agreement may be waived or
amended only with the written consent of the parties.

      4.6 Entire Agreement. This Agreement constitutes the full and entire
understanding and agreement between the parties with regard to the subjects
hereof, and no party shall be liable or bound to any other party in any manner
by warranties, representations, or covenants except as specifically set forth
herein. In addition to this Agreement, the existing Collaboration Agreement,
dated as of November 19, 2001, between the Company and the University regarding
the area of DNA methylation, the Master Clinical Trial Research Agreement, first
dated as of March 9, 1995, between the University and the Company, and the
related protocol, confidentiality and other agreements between the University
and the Company, shall each remain and continue in full force and effect after
the date hereof in accordance with their terms.

                                      -6-
<PAGE>

      4.7 Notices. Any notice required by this Agreement shall be effective upon
deposit in the U.S. mail when given by prepaid, first class, certified mail,
return receipt requested, addressed to:

If to the University: Michael B. Amey
                      Associate Dean for Research Administration
                      The Johns Hopkins University School of Medicine
                      733 N Broadway Avenue, BRB 117
                      Baltimore, Maryland 21205

with a copy to:       Martin D. Abeloff, M.D.
                      Professor and Director
                      Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
                      401 N Broadway, Weinberg 1100
                      Baltimore, Maryland 21231-2410

If to the Company:    Frederick H. Hausheer, M.D.
                      Chairman and Chief Executive Officer
                      BioNumerik Pharmaceuticals, Inc.
                      8122 Datapoint Drive, Suite 1250
                      San Antonio, Texas 78229

      4.8 Governing Law. This Agreement shall be governed in all respects by and
construed in accordance with the laws of the State of Maryland as applied to
agreements among Maryland residents to be performed entirely in Maryland.

      4.9 Headings. The headings of the several sections of this Agreement are
intended for convenience of reference only and are not intended to be a part of
or to affect the meaning or interpretation of this Agreement.

      4.10 Severability. If any provision of this Agreement shall be found by a
court to be void, invalid, or unenforceable, the validity, legality, and
enforceability of the remaining provisions shall not be in any way affected or
impaired thereby.

      4.11 Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed an original, but each of which together shall constitute
one and the same instrument.

                                      -7-
<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

THE JOHNS HOPKINS UNIVERSITY           BIONUMERIK PHARMACEUTICALS, INC.

By: /s/ MICHAEL B. AMEY                By: /s/ FREDERICK H. HAUSHEER
    ------------------------------         -------------------------------------
Name: Michael B. Amey                  Name: Frederick H. Hausheer, M.D.
Title: Associate Dean                  Title: Chairman & Chief Executive Officer

Date:    3-8-05                        Date:    2-28-05
      ------------                           -------------
The undersigned have read this Agreement and agree to its terms:

/s/ MARTIN D. ABELOFF
___________________________________
Martin D. Abeloff, M.D.

/s/ STEPHEN BAYLIN
___________________________________
Stephen Baylin, M.D.

                                      -8-exv10w4

 

EXHIBIT 10.4

CARRIER ACCESS CORPORATION

INDEMNIFICATION AGREEMENT

      This Indemnification Agreement (the “Agreement”) is effective as of January 21, 2005 by
and between Carrier Access Corporation, a Delaware corporation (the “Company”) and David R. Laube
(the “Indemnitee”).

      WHEREAS, the Company desires to attract and retain the services of highly qualified
individuals, such as Indemnitee, to serve the Company and its related entities;

      WHEREAS, in order to induce Indemnitee to continue to provide services to the Company, the
Company wishes to provide for the indemnification of, and the advancement of expenses to,
Indemnitee to the maximum extent permitted by law;

      WHEREAS, the Company and Indemnitee recognize the continued difficulty in obtaining liability
insurance for the Company’s directors, officers, employees, agents and fiduciaries, the significant
increases in the cost of such insurance and the general reductions in the coverage of such
insurance;

      WHEREAS, the Company and Indemnitee further recognize the substantial increase in corporate
litigation in general, subjecting directors, officers, employees, agents and fiduciaries to
expensive litigation risks at the same time as the availability and coverage of liability insurance
has been severely limited; and

      WHEREAS, in view of the considerations set forth above, the Company desires that Indemnitee
shall be indemnified and advanced expenses by the Company as set forth herein;

      NOW, THEREFORE, the Company and the Indemnitee hereby agree as set forth below.

      1. Certain Definitions

                 (a) “Change in Control” shall mean an event that shall be deemed to have occurred if, on or
after the date of this Agreement, (i) any “person” (as such term is used in Sections 13(d) and
14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than a
trustee or other fiduciary holding securities under an employee benefit plan of the company acting
in such capacity or a corporation owned directly or indirectly by the stockholders of the Company
in substantially the same proportions as their ownership of stock of the Company, who becomes the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of the Company representing more than 50% of the total voting power represented by the
Company’s then outstanding Voting Securities, (ii) during any period of two consecutive years,
individuals who at the beginning of such period constitute the Board of Directors of the Company
and any new director whose election by the Board of Directors or nomination for election by the
Company’s stockholders was approved by a vote of at least two thirds (2/3) of the directors then
still in office who either were directors at the beginning of the period or whose election or
nomination for election was previously so approved cease for any reason to constitute a majority
thereof, or (iii) the stockholders of the Company approve a merger or consolidation of the Company
with any other corporation, other than a merger or consolidation which would result in the Voting
Securities of the Company outstanding or immediately prior thereto continuing to represent (either
remaining outstanding or by being converted into Voting Securities of the surviving entity) at
least 80% of the total voting power represented by the Voting Securities of the Company or such
surviving entity outstanding immediately after such merger or consolidation, or the stockholders of
the Company approve a plan of complete liquidation of the Company or an agreement for the

 

 

sale or disposition by the Company of (in one transaction or a series of related transactions)
all or substantially all of the Company’s assets.

                 (b) “Claim” shall mean, with respect to a Covered Event, any threatened, pending or completed
action, suit, proceeding or alternative dispute resolution mechanism, or any hearing, inquiry or
investigation that Indemnitee in good faith believes might lead to the institution of any such
action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal,
administrative, investigative or other.

                 (c) References to the “Company” shall include, in addition to Carrier Access Corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or
merger to which Carrier Access Corporation (or any of its wholly owned subsidiaries) is a party
which, if its separate existence had continued, would have had power and authority to indemnify its
directors, officers, employees, agents or fiduciaries, so that if Indemnitee is or was a director,
officer, employee, agent or fiduciary of such constituent corporation, or is or was serving at the
request of such constituent corporation as a director, officer, employee, agent or fiduciary of
another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise,
Indemnitee shall stand in the same position under the provisions of this Agreement with respect to
the resulting or surviving corporation as Indemnitee would have with respect to such constituent
corporation if its separate existence had continued.

                 (d) “Covered Event” shall mean any event or occurrence related to the fact that Indemnitee is
or was a director, officer, employee, agent or fiduciary of the Company, or any subsidiary of the
Company, or is or was serving at the request of the Company as a director, officer, employee, agent
or fiduciary of another corporation, partnership, joint venture, trust or other enterprise, or by
reason of any action or inaction on the part of Indemnitee while serving in such capacity.

                 (e) “Expenses” shall mean any and all expenses (including attorneys’ fees and all other costs,
expenses and obligations incurred in connection with investigating, defending, being a witness in
or participating in (including on appeal), or preparing to defend, to be a witness in or to
participate in, any action, suit, proceeding, alternative dispute resolution mechanism, hearing,
inquiry or investigation), judgments, fines, penalties and amounts paid in settlement (if such
settlement is approved in advance by the Company, which approval shall not be unreasonably
withheld), actually and reasonably incurred, of any Claim and any federal, state, local or foreign
taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under
this Agreement.

                 (f) “Expense Advance” shall mean a payment to Indemnitee, pursuant to Section 3, of Expenses
in advance of the settlement of or final judgment in any action, suit, proceeding or alternative
dispute resolution mechanism, hearing, inquiry or investigation which constitutes a Claim.

                 (g) “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in
accordance with the provisions of Section 2(d) hereof, who shall not have otherwise performed
services for the Company or Indemnitee within the last three years (other than with respect to
matters concerning the rights of Indemnitee under this Agreement, or of other indemnitees under
similar indemnity agreements). Such Independent Legal Counsel shall not include any person who,
under the applicable standards of professional conduct then prevailing, would have a conflict of
interest in representing either the Company or the Indemnitee in an action to determine the
Indemnitee’s rights under this Agreement.

                 (h) References to “other enterprises” shall include employee benefit plans; references to
“fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit
plan; and references to “serving at the request of the Company” shall include any service as a
director, officer, employee, agent or fiduciary of the Company which imposes duties on, or involves
services by, such director, officer, employee, agent or fiduciary with respect to an employee
benefit plan, its participants or its beneficiaries; and if Indemnitee acted in good faith and in a
manner Indemnitee reasonably believed to be in

-2-

 

the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee
shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as
referred to in this Agreement.

                 (i) “Reviewing Party” shall mean, subject to the provisions of Section 2(d), any person or
body appointed by the Board of Directors in accordance with applicable law to review the Company’s
obligations hereunder and under applicable law, which may include a member or members of the
Company’s Board of Directors or Independent Legal Counsel.

                 (j) “Section” refers to a section of this Agreement unless otherwise indicated.

                 (k) “Voting Securities” shall mean any securities of the Company that vote generally in the
election of directors.

      2. Indemnification.

                 (a) Indemnification of Expenses. Subject to the provisions of Section 2(b) below, the
Company shall indemnify Indemnitee for Expenses to the fullest extent permitted by law if
Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened to
be made a party to or witness or other participant in, any Claim (whether by reason of or arising
in part out of a Covered Event), including all interest, assessments and other charges paid or
payable in connection with or in respect of such Expenses.

                 (b) Review of Indemnification Obligations. Notwithstanding the foregoing, in the
event a Reviewing Party shall have determined pursuant to Section 145(d) of the General Corporation
Law of the State of Delaware (in a written opinion, in any case in which Independent Legal Counsel
is the Reviewing Party) that Indemnitee is not entitled to be indemnified hereunder under
applicable law, (i) the Company shall have no further obligation under Section 2(a) to make any
payments to Indemnitee not made prior to such determination by such Reviewing Party, and (ii) the
Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse the
Company) for all Expenses theretofore paid in indemnifying Indemnitee; provided,
however, that if Indemnitee has commenced or thereafter commences legal proceedings in a
court of competent jurisdiction to secure a determination that Indemnitee is entitled to be
indemnified hereunder under applicable law in accordance with Section 2(c), then any determination
made by any Reviewing Party that, under applicable law, Indemnitee is not entitled to be
indemnified hereunder shall not be binding, and, until a final judicial determination is made with
respect to such legal proceedings (as to which all rights of appeal therefrom have been exhausted
or lapsed), (x) Indemnitee shall not be required to reimburse the Company for any Expenses
theretofore paid in indemnifying Indemnitee and (y) Indemnitee shall be entitled to receive interim
payments of Expenses pursuant to Section 2(a). Indemnitee’s obligation to reimburse the Company
for any Expenses shall be unsecured and no interest shall be charged thereon.

                 (c) Indemnitee Rights on Unfavorable Determination; Binding Effect. If a Reviewing
Party determines that Indemnitee is not entitled to be indemnified hereunder in whole or in part
under applicable law, Indemnitee shall have the right to commence litigation seeking an initial
determination by the court or challenging any such determination by such Reviewing Party or any
aspect thereof, including the legal or factual bases therefor, and, subject to the provisions of
Section 15, the Company hereby consents to service of process and to appear in any such proceeding.

                 (d) Selection of Reviewing Party; Change in Control.

	 	(i)  	If there has not been a Change in Control, any
Reviewing Party shall be selected by the Board of Directors.
	 
	 	(ii)  	If there has been such a Change in Control (other
than a Change in Control which has been approved by a majority of the
Company’s Board of Directors who were directors immediately prior to
such Change in Control), any Reviewing Party with respect to all matters
thereafter arising concerning the rights of Indemnitee

-3-

 

	 	   	to indemnification of Expenses under this Agreement or any other
agreement, or under the Company’s Certificate of Incorporation or Bylaws
as now or hereafter in effect, or under any other applicable law, if
desired by Indemnitee, shall be Independent Legal Counsel selected by
Indemnitee and approved by the Company (which approval shall not be
unreasonably withheld).
	 
	 	(iii)  	If the parties are unable to agree upon the
Independent Legal Counsel under Section 2.(d)(ii) above, or if there has
been such a Change in Control which was approved by a majority of the
Company’s Board of Directors who were directors immediately prior to
such Change in Control, the Independent Legal Counsel shall be selected
by lot from among at least five (5) law firms with offices in the State
of Delaware having more than fifty (50) attorneys, having a rating of
“av” or better in the then current Martindale Hubbell Law Directory and
having attorneys which specialize in corporate law. Such selection
shall be made in the presence of Indemnitee (and his legal counsel or
either of them, as Indemnitee may elect).

	 	   	Such Independent Legal Counsel, among other things, shall render its written opinion
within ninety (90) days of its retention to the Company and Indemnitee as to whether
and to what extent Indemnitee would be entitled to be indemnified hereunder under
applicable law and the Company agrees to abide by such opinion. The Company agrees
to pay the reasonable fees of the Independent Legal Counsel referred to above and to
indemnify fully such counsel against any and all expenses (including attorneys’
fees), claims, liabilities and damages arising out of or relating to this Agreement
or its engagement pursuant hereto. Notwithstanding any other provision of this
Agreement, the Company shall not be required to pay Expenses of more than one
Independent Legal Counsel in connection with all matters concerning a single
Indemnitee, and such Independent Legal Counsel shall be the Independent Legal Counsel
for any or all other Indemnitees unless (i) the Company otherwise determines or (ii)
any Indemnitee shall provide a written statement setting forth in detail a reasonable
objection to such Independent Legal Counsel representing other indemnitees.

                 (e) Mandatory Payment of Expenses. Notwithstanding any other provision of this
Agreement other than Section 10 hereof, to the extent that Indemnitee has been successful on the
merits or otherwise, including, without limitation, the dismissal of an action without prejudice,
in defense of any Claim, Indemnitee shall be indemnified against all Expenses incurred by
Indemnitee in connection therewith.

      3. Expense Advances.

                 (a) Obligation to Make Expense Advances. Upon receipt of a written undertaking by or
on behalf of the Indemnitee to repay such amounts if it shall ultimately be determined that the
Indemnitee is not entitled to be indemnified therefor by the Company, the Company shall make
Expense Advances to Indemnitee.

                 (b) Form of Undertaking. Any obligation to repay any Expense Advances hereunder
pursuant to a written undertaking by the Indemnitee shall be unsecured and no interest shall be
charged thereon.

                 (c) Determination of Reasonable Expense Advances. The parties agree that for the
purposes of any Expense Advance for which Indemnitee has made written demand to the Company in
accordance with this Agreement, all Expenses included in such Expense Advance that are certified by
affidavit of Indemnitee’s counsel as being reasonable shall be presumed conclusively to be
reasonable.

-4-

 

      4. Procedures for Indemnification and Expense Advances.

                 (a) Timing of Payments. All payments of Expenses (including, without limitation,
Expense Advances) by the Company to the Indemnitee pursuant to this Agreement shall be made to the
fullest extent permitted by law as soon as practicable after written demand by Indemnitee therefor
is presented to the Company, but in no event later than forty-five (45) business days after such
written demand by Indemnitee is presented to the Company, except in the case of Expense Advances,
which shall be made no later than twenty (20) days after such written demand by Indemnitee is
presented to the Company.

                 (b) Notice/Cooperation by Indemnitee. Indemnitee shall, as a condition precedent to
Indemnitee’s right to be indemnified or Indemnitee’s right to receive Expense Advances under this
Agreement, give the Company notice in writing as soon as practicable of any Claim made against
Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the
Company shall be directed to the Chief Executive Officer of the Company at the address shown on the
signature page of this Agreement (or such other address as the Company shall designate in writing
to Indemnitee). In addition, Indemnitee shall give the Company such information and cooperation as
it may reasonably require and as shall be within Indemnitee’s power.

                 (c) No Presumptions; Burden of Proof. For purposes of this Agreement, the termination
of any Claim by judgment, order, settlement (whether with or without court approval) or conviction,
or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that
Indemnitee did not meet any particular standard of conduct or have any particular belief or that a
court has determined that indemnification is not permitted by this Agreement or applicable law. In
addition, it is the parties’ intention that if Indemnitee commences legal proceedings to secure a
judicial determination that Indemnitee should be indemnified under this Agreement or applicable
law, the question of Indemnitee’s right to indemnification shall be for the court to decide, and
neither the failure of any Reviewing Party to have made a determination as to whether Indemnitee
has met any particular standard of conduct or had any particular belief, nor an actual
determination by any Reviewing Party that Indemnitee has not met such standard of conduct or did
not have such belief, , shall be a defense to Indemnitee’s claim or create a presumption that
Indemnitee has not met any particular standard of conduct or did not have any particular belief.
In connection with any determination by any Reviewing Party or otherwise as to whether the
Indemnitee is entitled to be indemnified hereunder, the burden of proof shall be on the Company to
establish by clear and convincing evidence that Indemnitee is not so entitled.

                 (d) Notice to Insurers. If, at the time of the receipt by the Company of a notice of
a Claim pursuant to Section 4(b) hereof, the Company has liability insurance in effect which may
cover such Claim, the Company shall give prompt notice of the commencement of such Claim to the
insurers in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the
Indemnitee, all amounts payable as a result of such Claim in accordance with the terms of such
policies.

                 (e) Selection of Counsel. In the event the Company shall be obligated hereunder to
provide indemnification for or make any Expense Advances with respect to the Expenses of any Claim,
the Company, if appropriate, shall be entitled to assume the defense of such Claim with counsel
approved by Indemnitee (which approval shall not be unreasonably withheld) upon the delivery to
Indemnitee of written notice of the Company’s election to do so. If the Indemnitee objects to
counsel selected by Company, Company shall provide a list at least three (3) other attorneys or
firms of attorneys for Indemnitee approval, and Indemnitee shall be required to approve one (1) of
the three (3) attorneys or firms of attorneys to serve as counsel under this provision or offer an
alternative selection of counsel for approval by Company. If the parties are unable to mutually
approve the selection of counsel hereunder, counsel shall be determined by the following person or
persons who shall be empowered to make such determination: (a) the Board of Directors of the
Company by a majority vote of Disinterested Directors (defined in Section 2(d)(iii) above), whether
or not such majority constitutes a quorum; (b) a committee of Disinterested Directors designated by
a majority vote of such directors, whether or not such majority constitutes a quorum; or (c) the
stockholders of The

-5-

 

Company. Upon failure to select such counsel under this provision, such counsel shall be
selected upon application to a court of competent jurisdiction. After delivery of such notice,
approval of such counsel by Indemnitee and the retention of such counsel by the Company, the
Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate
counsel subsequently employed by or on behalf of Indemnitee with respect to the same Claim;
provided that (i) Indemnitee shall have the right to employ Indemnitee’s separate counsel in any
such Claim at Indemnitee’s expense and (ii) if (A) the employment of separate counsel by Indemnitee
has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that
there may be a conflict of interest between the Company and Indemnitee in the conduct of any such
defense, or (C) the Company shall not continue to retain such counsel to defend such Claim, then
the fees and expenses of Indemnitee’s separate counsel shall be Expenses for which Indemnitee may
receive indemnification or Expense Advances hereunder.

      5. Additional Indemnification Rights; Nonexclusivity.

                 (a) Scope. The Company hereby agrees to indemnify the Indemnitee to the fullest
extent permitted by law, notwithstanding that such indemnification is not specifically authorized
by the other provisions of this Agreement, the Company’s Certificate of Incorporation, the
Company’s Bylaws or by statute. In the event of any change after the date of this Agreement in any
applicable law, statute or rule which expands the right of a Delaware corporation to indemnify a
member of its board of directors or an officer, employee, agent or fiduciary, it is the intent of
the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits afforded by
such change. In the event of any change in any applicable law, statute or rule which narrows the
right of a Delaware corporation to indemnify a member of its board of directors or an officer,
employee, agent or fiduciary, such change, to the extent not otherwise required by such law,
statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the
parties’ rights and obligations hereunder except as set forth in Section 10(a) hereof.

                 (b) Nonexclusivity. The indemnification and the payment of Expense Advances provided
by this Agreement shall be in addition to any rights to which Indemnitee may be entitled under the
Company’s Certificate of Incorporation, its Bylaws, any other agreement, any vote of stockholders
or disinterested directors, the General Corporation Law of the State of Delaware, or otherwise.
The indemnification and the payment of Expense Advances provided under this Agreement shall
continue as to Indemnitee for any action taken or not taken while serving in an indemnified
capacity even though subsequent thereto Indemnitee may have ceased to serve in such capacity.

      6. No Duplication of Payments. The Company shall not be liable under this Agreement
to make any payment in connection with any Claim made against Indemnitee to the extent Indemnitee
has otherwise actually received payment (under any insurance policy, provision of the Company’s
Certificate of Incorporation, Bylaws or otherwise) of the amounts otherwise payable hereunder.

      7. Partial Indemnification. If Indemnitee is entitled under any provision of this
Agreement to indemnification by the Company for some or a portion of Expenses incurred in
connection with any Claim, but not, however, for all of the total amount thereof, the Company shall
nevertheless indemnify Indemnitee for the portion of such Expenses to which Indemnitee is entitled.

      8. Mutual Acknowledgement. Both the Company and Indemnitee acknowledge that in
certain instances, federal law or applicable public policy may prohibit the Company from
indemnifying its directors, officers, employees, agents or fiduciaries under this Agreement or
otherwise. Indemnitee understands and acknowledges that the Company has undertaken or may be
required in the future to undertake with the Securities and Exchange Commission to submit the
question of indemnification to a court in certain circumstances for a determination of the
Company’s right under public policy to indemnify Indemnitee.

      9. Liability Insurance. To the extent the Company maintains liability insurance
applicable to directors, officers, employees, agents or fiduciaries, Indemnitee shall be covered by
such policies in such a manner as to provide Indemnitee the same rights and benefits as are
provided to the most favorably insured of

-6-

 

the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if
Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees,
agents or fiduciaries, if Indemnitee is not an officer or director but is a key employee, agent or
fiduciary.

      10. Exceptions. Notwithstanding any other provision of this Agreement, the Company
shall not be obligated pursuant to the terms of this Agreement:

                 (a) Excluded Action or Omissions. To indemnify Indemnitee for Expenses resulting from
acts, omissions or transactions for which Indemnitee is prohibited from receiving indemnification
under this Agreement, the Company’s Certificate of Incorporation or Bylaws, or applicable law;
provided, however, that notwithstanding any limitation set forth in this Section
10(a) regarding the Company’s obligation to provide indemnification, Indemnitee shall be entitled
under Section 3 to receive Expense Advances hereunder with respect to any such Claim unless and
until a court having jurisdiction over the Claim shall have made a final judicial determination (as
to which all rights of appeal therefrom have been exhausted or lapsed) that Indemnitee has engaged
in acts, omissions or transactions for which Indemnitee is prohibited from receiving
indemnification under this Agreement or applicable law.

                 (b) Claims Initiated by Indemnitee. To indemnify or make Expense Advances to
Indemnitee with respect to Claims initiated or brought voluntarily by Indemnitee and not by way of
defense, counterclaim or crossclaim, except (i) with respect to actions or proceedings brought to
establish or enforce a right to indemnification under this Agreement or any other agreement or
insurance policy or under the Company’s Certificate of Incorporation or Bylaws now or hereafter in
effect relating to Claims for Covered Events, (ii) in specific cases if the Board of Directors has
approved the initiation or bringing of such Claim, or (iii) as otherwise required under Section 145
of the General Corporation Law of the State of Delaware, regardless of whether Indemnitee
ultimately is determined to be entitled to such indemnification or insurance recovery, as the case
may be.

                 (c) Lack of Good Faith. To indemnify Indemnitee for any Expenses incurred by the
Indemnitee with respect to any action instituted (i) by Indemnitee to enforce or interpret this
Agreement, if a court having jurisdiction over such action determines as provided in Section 13
that each of the material assertions made by the Indemnitee as a basis for such action was not made
in good faith or was frivolous, or (ii) by or in the name of the Company to enforce or interpret
this Agreement, if a court having jurisdiction over such action determines as provided in Section
13 that each of the material defenses asserted by Indemnitee in such action was made in bad faith
or was frivolous.

                 (d) Claims Under Section 16(b). To indemnify Indemnitee for expenses and the payment
of profits arising from the purchase and sale by Indemnitee of securities in violation of Section
16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute;
provided, however, that notwithstanding any limitation set forth in this Section
10(d) regarding the Company’s obligation to provide indemnification, Indemnitee shall be entitled
under Section 3 to receive Expense Advances hereunder with respect to any such Claim unless and
until a court having jurisdiction over the Claim shall have made a final judicial determination (as
to which all rights of appeal therefrom have been exhausted or lapsed) that Indemnitee has violated
said statute.

      11. Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall constitute an original.

      12. Binding Effect; Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of and be enforceable by the parties hereto and their respective successors,
assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise
to all or substantially all of the business or assets of the Company), spouses, heirs and personal
and legal representatives. The Company shall require and cause any successor (whether direct or
indirect, and whether by purchase, merger, consolidation or otherwise) to all, substantially all,
or a substantial part, of the business or assets of the Company, by written agreement in form and
substance satisfactory to Indemnitee, expressly to assume and

-7-

 

agree to perform this Agreement in the same manner and to the same extent that the Company
would be required to perform if no such succession had taken place. This Agreement shall continue
in effect regardless of whether Indemnitee continues to serve as a director, officer, employee,
agent or fiduciary (as applicable) of the Company or of any other enterprise at the Company’s
request.

      13. Expenses Incurred in Action Relating to Enforcement or Interpretation. In the
event that any action is instituted by Indemnitee under this Agreement or under any liability
insurance policies maintained by the Company to enforce or interpret any of the terms hereof or
thereof, Indemnitee shall be entitled to be indemnified for all Expenses incurred by Indemnitee
with respect to such action (including without limitation attorneys’ fees), regardless of whether
Indemnitee is ultimately successful in such action, unless as a part of such action a court having
jurisdiction over such action makes a final judicial determination (as to which all rights of
appeal therefrom have been exhausted or lapsed) that each of the material assertions made by
Indemnitee as a basis for such action was not made in good faith or was frivolous;
provided, however, that until such final judicial determination is made, Indemnitee
shall be entitled under Section 3 to receive payment of Expense Advances hereunder with respect to
such action. In the event of an action instituted by or in the name of the Company under this
Agreement to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled
to be indemnified for all Expenses incurred by Indemnitee in defense of such action (including
without limitation costs and expenses incurred with respect to Indemnitee’s counterclaims and
cross-claims made in such action), unless as a part of such action a court having jurisdiction over
such action makes a final judicial determination (as to which all rights of appeal therefrom have
been exhausted or lapsed) that each of the material defenses asserted by Indemnitee in such action
was made in bad faith or was frivolous; provided, however, that until such final
judicial determination is made, Indemnitee shall be entitled under Section 3 to receive payment of
Expense Advances hereunder with respect to such action.

      14. Notice. All notices, requests, demands and other communications under this
Agreement shall be in writing and shall be deemed duly given (i) if delivered by hand and signed
for by the party addressed, on the date of such delivery, or (ii) if mailed by domestic certified
or registered mail with postage prepaid, on the third business day after the date postmarked.
Addresses for notice to either party are as shown on the signature page of this Agreement, or as
subsequently modified by written notice.

      15. Consent to Jurisdiction. The Company and Indemnitee each hereby irrevocably
consent to the jurisdiction of the courts of the State of Delaware for all purposes in connection
with any action or proceeding which arises out of or relates to this Agreement and agree that any
action instituted under this Agreement shall be commenced, prosecuted and continued only in the
Court of Chancery of the State of Delaware in and for New Castle County, which shall be the
exclusive and only proper forum for adjudicating such a claim.

      16. Severability. The provisions of this Agreement shall be severable in the event
that any of the provisions hereof (including any provision within a single section, paragraph or
sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise
unenforceable, and the remaining provisions shall remain enforceable to the fullest extent
permitted by law. Furthermore, to the fullest extent possible, the provisions of the Agreement
(including without limitation each portion of this Agreement containing any provision held to be
invalid, void or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall
be construed so as to give effect to the intent manifested by the provision held invalid, illegal
or unenforceable.

      17. Choice of Law. This Agreement, and all rights, remedies, liabilities, powers and
duties of the parties to this Agreement, shall be governed by and construed in accordance with the
laws of the State of Delaware without regard to principles of conflicts of laws.

      18. Subrogation. In the event of payment under this Agreement, the Company shall
be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who
shall execute all

-8-

 

documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring
suit to enforce such rights.

      19. Amendment and Termination. No amendment, modification, termination or cancellation of this Agreement shall be effective unless
it is in writing signed by both the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed to be or shall
constitute a waiver of any other provisions hereof (whether or not similar), nor shall such waiver constitute a continuing waiver.

      20. Integration and Entire Agreement. This Agreement sets forth the entire understanding between the parties hereto and supersedes and merges all
previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the parties hereto.

      21. No Construction as Employment Agreement. Nothing contained in this Agreement shall be construed as giving Indemnitee any
right to be retained in the employ of the Company or any of its subsidiaries or affiliated entities.

      IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement as of the date first above written.

	 	 	 	 	 	 	 
	CARRIER ACCESS CORPORATION

	 
	 	 	 	 	 	 
	By:

	 		 	 	 	 
	

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	Roger L. Koenig	 	 	 	 
	

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Title:

	 	Chairman of the Board, CEO & President	 	 	 	 
	

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Address:

	 	5395 Pearl Parkway	 	 	 	 
	

	 	 	 	 	 	 
	

	 	Boulder, CO 80301	 	 	 	 
	

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	AGREED TO AND ACCEPTED
	 
	 	 	 	 	 	 
	 
	 	 	 	INDEMNITEE:
	 
	 	 	 	 	 	 
	 
	 	 	 	
	 
	 	 	 	 
	 
	 	 	 	(signature)
	 
	 	 	 	 	 	 
	

	 	 	 	Name:
	 	David R. Laube
	

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	

	 	 	 	Address:
	 	15825 W. Bayaud Drive
	

	 	 	 	 	 	 
	

	 	 	 	 	 	Golden, CO 80401
	

	 	 	 	 	 	 

-9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]